However, although immunotherapy plays an important role in the treatment of SCLC, considering that both SCLC-A and SCLC-N subtypes have been associated with limited benefit from immune checkpoint blockade therapy compared with the SCLC-inflamed subtype12, exploration of the consequences of ASCL1 and NEUROD1 co-expression in SCLC cells in the context of antitumor immunity was less of a priority. Here, NEUROD1 is linked to small cell lung carcinoma.